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Abstract
Attention-Deficit/Hyperactivity Disorder (ADHD) is a common neurodevelopmental disorder with only symptomatic care
available. Genome-wide association (GWA) studies can provide a starting point in the search for novel drug targets and
possibilities of drug repurposing. Here, we explored the druggable genome in ADHD by utilising GWA studies on ADHD
and its co-morbid conditions. First, we explored whether the genes targeted by current ADHD drugs show association with
the disorder and/or its co-morbidities. Second, we aimed to identify genes and pathways involved in the biological processes
underlying ADHD that can be targeted by pharmacological agents. These ADHD-associated druggable genes and pathways
were also examined in co-morbidities of ADHD, as commonalities in their aetiology and management may lead to novel
pharmacological insights. Strikingly, none of the genes encoding targets of first-line pharmacotherapeutics for ADHD were
significantly associated with the disorder, suggesting that FDA-approved ADHD drugs may act through different
mechanisms than those underlying ADHD. In the examined druggable genome, three loci on chromosomes 1, 4 and 12
revealed significant association with ADHD and contained nine druggable genes, five of which encode established drug
targets for malignancies, autoimmune and neurodevelopmental disorders. To conclude, we present a framework to assess the
druggable genome in a disorder, exemplified by ADHD. We highlight signal transduction and cell adhesion as potential
novel avenues for ADHD treatment. Our findings add to knowledge on known ADHD drugs and present the exploration of
druggable genome associated with ADHD, which may offer interventions at the aetiological level of the disorder.
Introduction
Attention deficit/hyperactivity disorder (ADHD) is a com-
mon and highly heritable childhood-onset neurodevelop-
mental disorder that often persists into adulthood [1, 2]. The
prevalence of the disorder in children is 6.5%, while in
adults the estimates vary between 2.5 and 3.4% [3]. ADHD
patients are at high risk of experiencing difficulties in their
education and social integration [4], elevated rates of
incarceration, unemployment and accidental deaths, all
resulting in high societal and economic burden [1, 5–7]. To
date, no treatments cure ADHD, although available thera-
pies offer symptomatic relief.
Current management of ADHD is based on either non-
pharmacologic or pharmacologic treatments as well as the
combination of the two. The non-pharmacologic treatments
usually involve psychological and/or behavioural therapies,
while the pharmacologic interventions include stimulant
and/or non-stimulant drugs [1, 8]. For ADHD treatment, the
U.S. Food and Drug Administration (FDA) has approved
the stimulants methylphenidate (MPH) and amphetamine
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(AMP) along with three non-stimulants: atomoxetine, clo-
nidine and guanfacine [9]. In many guidelines, MPH and
AMP are the first-line agents for ADHD pharmacotherapy,
exerting their primary effect by increasing dopamine and
norepinephrine activity [10, 11]. Atomoxetine is a selective
norepinephrine re-uptake inhibitor, while both clonidine
and guanfacine are alpha-2 adrenoreceptor agonists [11].
Although all the pharmaceuticals used to manage ADHD
are believed to act on biological pathways underlying the
disorder, their complete mechanisms of action remain
unknown, as are the causal biological mechanisms
of ADHD.
An important feature of ADHD relevant to the search of
new medications is the existence of co-morbid conditions
[12, 13]. As it has been postulated that biological processes
underlying ADHD may also be involved in the develop-
ment of its co-morbidities [14], it is prudent to examine the
relationship between ADHD-associated druggable loci and
those conditions. The exploration of associations between a
gene encoding or being the target of a drug and a number of
phenotypes has been proposed to aid pharmacotherapeutics
by capturing a broader spectrum of relevant biological
information and offering alternatives to existing pharma-
ceuticals to treat a disorder (drug repurposing) [15].
Randomised controlled studies have shown that phar-
macotherapy reduces the ADHD symptom burden [16] and
observational studies have reported that it improves
important life outcomes, such as academic performance
[17], social functioning [18, 19] and the rate of motor
vehicle accidents [20]. Nonetheless, the current pharmaco-
logical treatment of ADHD is not curative and, although
many patients improve markedly, optimal outcomes are
difficult to achieve, especially with regards to signs of
executive dysfunction and emotional dysregulation [21, 22].
There are also lingering concerns about long-term effects of
stimulants on growth and weight [23–25]. Thus, there is a
need for more efficient and safe pharmacological agents to
treat and, eventually, cure ADHD.
Improvements in the pharmacotherapeutic options for
ADHD may require a fuller understanding of its underlying
biological processes [26]. As knowledge on the genetics of
common disorders evolves, novel strategies for the devel-
opment of new and improved pharmacotherapeutics are
emerging. For complex disorders, such as ADHD, genome-
wide association (GWA) studies can uncover genes and
pathways involved in the disease aetiology, yielding inno-
vative avenues for future drug development and repurpos-
ing [27, 28].
In this study, we explored the druggable genome in
ADHD by utilising the summary statistics from GWA stu-
dies on ADHD and its major co-morbid conditions. We
aimed to (1) explore whether the genes targeted by current
FDA-approved ADHD drugs show association with the
disorder and/or its co-morbidities, (2) identify genes and
pathways involved in the biological processes underlying
ADHD, its co-morbidities and quality of life phenotypes
that can be targeted by pharmacological compounds and (3)
examine the identified druggable genes and pathways as
potential options for novel drug development and
repurposing.
Materials and methods
Figure 1 shows a flowchart summarising the steps of our
study.
Definition of the druggable genome
The druggable genome was defined as described in Finan
et al. [29] as a selection of genes that are potential targets
for pharmacological intervention.
The identification of these druggable genes was based on
the protein targets of known and experimental drugs,
sequence similarities to those targets (potential drugg-
ability), drug–gene interactions, biotherapeutics and a
number of databases documenting pharmacological mole-
cules and their therapeutic targets.
Definition of ADHD co-morbidities and quality of life
phenotypes
For the purpose of this study, we focused only on common
conditions with well-documented evidence for association
with ADHD based on large-scale genetic [30] and epide-
miological [31] studies, together with a systematic literature
review [32] complemented by a PubMed search using the
following criteria “((ADHD co-morbidity) AND English
[Language]) AND (“2015” [Date-Publication]: “3000”
[Date-Publication])”.
Additional criteria were the availability of large (≥20,000
individuals) GWA studies and their summary statistics.
Thus, where such data were not available, we used proxy
phenotypes (e.g. instead of insomnia disorder, we examined
insomnia symptoms [33]).
We characterised the co-morbidities into the three main
groups: (1) cardiometabolic, (2) immune-inflammatory-
autoimmune (referred to as immune) and (3)
neuropsychiatric.
In addition to well-defined clinical diagnoses, ADHD has
been reported to be associated with reduced quality of life,
reduced educational attainment and sleep disturbances [1].
Therefore, we also examined the druggable genome over-
lapping between ADHD and educational attainment, sleep
duration and subjective well-being as proxies for quality of
life and functional outcomes associated with ADHD.
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Genetic data
We relied on summary statistics derived from large-scale
GWA studies. Where possible, we restricted our analyses to
individuals of European descent only, meta-analysed sam-
ple size equal to or larger than 70% of the total sample,
variants with minor allele frequency above or equal to 1%
and of good imputation quality (INFO ≥ 0.8). For ADHD,
summary statistics were acquired from the large-scale meta-
analysis of 19,099 cases and 34,194 controls [30]. For the
co-morbidities, we curated data from openly available
resources or through correspondence with the authors of the
GWA studies of interest (Table 1).
Statistical analyses
Statistical analyses were divided into two main steps to
address our first two aims: (1) examination of genes targeted
by current FDA-approved ADHD drugs and (2)
examination of the genes within the druggable genome and
their pathways defined as known biological pathways con-
taining at least one gene from the druggable genome. In step
1, we examined all genes in all curated GWA data. In step
2, we first examined ADHD and only genes and pathways
that revealed suggestive association with it (p ≤ 0.001) were
further analysed in the GWA data of its co-morbidities and
quality of life phenotypes. We applied Bonferroni correc-
tion to account for multiple testing.
Step one: analyses of the genes targeted by current ADHD
drugs
The genes targeted by the current FDA-approved ADHD
medications were defined by Gaspar and Breen [34]. We
examined these genes individually (gene-based tests) and
altogether (gene-set analyses) in MAGMA software [35].
Each gene’s degree of association with a phenotype was
calculated based on the individual single nucleotide
Fig. 1 Study design flowchart. ADHD; attention deficit/hyperactivity disorder, BMI; body mass index, CHD; coronary heart disease, T2DM; type
2 diabetes mellitus, SWB; subjective well-being
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polymorphisms’ (SNP) association p-values from their
respective GWA studies. SNPs with chromosomal posi-
tions within the boundaries of a gene (start and end of a
primary transcript) were assigned to that gene (i.e. the
default settings of MAGMA). The 1000 Genomes CEU
population was used as the reference panel to correct for
linkage disequilibrium (LD). We conducted gene-based
analyses of all genes on autosomal chromosomes. Genes
represented by a single parameter (i.e. only one association
signal) in MAGMA were excluded. To evaluate each
gene’s contribution to the examined gene-set, the associa-
tion p-value of each gene was converted to a Z-value and
used as an outcome variable for a regression model with
gene-set membership as a predictor. Gene size, gene-sets’
gene density and LD were taken into account to adjust for
possible confounding effects and prevent spurious
association.
Step two: analyses of genes and pathways within the
druggable genome
The gene associations with ADHD, its co-morbidities and
quality of life phenotypes were tested on two levels: (a)
DNA variation and (b) gene expression. The first was tested
in MAGMA as described above. The latter was tested in S-
PrediXcan [36]. In short, S-PrediXcan first predicts tissue-
specific gene expression level of each gene based on the
reference transcriptome data [37] and then estimates the
correlation between that level and a phenotype using GWA
summary statistics. Given that ADHD is believed to be a
disorder of the central nervous system, we restricted our S-
PrediXcan analyses to its tissues. S-PrediXcan analyses
were performed using the default settings of the software.
Type 2 diabetes was excluded from these analyses as the
available summary statistics did not contain the
necessary data.
The biological pathways were defined as determined by
Gene Ontology (GO) [38] and the Kyoto encyclopaedia of
genes and genomes (KEGG) [39]. We restricted our ana-
lyses to pathways represented by more than 10 and less than
1000 genes. The analyses were conducted in MAGMA [35]
as described above.
Characterisation of the druggable genome loci associated
with ADHD and/or its co-morbidities and quality of life
phenotypes
To address our third aim, we explored the pharmacology of
genes (or their encoded proteins) pinpointed in our statis-
tical analyses.
To identify the pharmacological agents, we developed a
systematic pipeline utilising publically available databases,
where the agents were assessed in four stages: (1) FDA-
approved drugs, (2) drugs in clinical trials, (3) compounds
reported in the Drug–Gene Interaction Database (DGIdb,
http://dgidb.org/), and (4) small molecule compounds with
reported molarity measurement for bioactivity.
First, we evaluated each gene of interest in Uniprot
(https://www.uniprot.org/) and characterised the identified
FDA-approved drugs and compounds in clinical trials using
Drugbank (https://www.drugbank.ca/), CLUE Repurposing
Hub (https://clue.io/repurposing-app), and DGIdb databases.
The FDA approval and clinical trial status of the compounds
were crosschecked using the publically available FDA labels
and ClinicalTrials.gov (https://clinicaltrials.gov/) database.
The paediatric approval status was investigated on Meds-
cape (https://reference.medscape.com/) and in FDA labels.
For FDA-approved compounds, the approved indication
reported in FDA label was noted. For compounds in clinical
trials, the indication was researched in ClinicalTrials.gov,
applying the following filters: “not yet recruiting”,
“recruiting”, “enroling by invitation”, “active, not recruit-
ing” and “completed”, in order to select trials that are cur-
rently active. In addition, the mechanism of action on the
specific gene of interest was noted from Drugbank.
Next, the genes were researched as targets in ChEMBL
(https://www.ebi.ac.uk/chembl/), downloading all com-
pounds reported to interact with a gene of interest along
with their reported “Target Associated Bioactivity” as their
affinity or potency to the human gene product stated in
molarity (referred to as “Bioactivity”). The compounds
from ChEMBL were then prioritised from the lowest
“Bioactivity” value to the highest and, in order to investi-
gate the most relevant compounds, the top 50 were char-
acterised further by being individually investigated in
PubChem (https://pubchem.ncbi.nlm.nih.gov/) to confirm
their target-associated bioactivity.
Results
Definition of druggable genome and ADHD co-
morbidities
The druggable human genome has been estimated to com-
prise 4479 genes [29], 3826 of which were represented by
more than one association signal in the ADHD GWA data.
These genes were present in 2758 pathways (2560 GO and
198 KEGG).
Genetic data
We obtained summary statistics from GWA studies for
ADHD, eight neuropsychiatric disorders, three cardiome-
tabolic diseases, five immune diseases and three quality of
life phenotypes (Table 1).
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Statistical analyses
In ADHD, we examined 3826 genes and 2759 gene sets in
the druggable genome (2560 GO, 198 KEGG and one set of
genes targeted by FDA-approved ADHD drugs), bringing the
Bonferroni-corrected significance threshold to p= 7.59E−06.
In the co-morbidities and quality of life phenotypes, we
examined 385 genes and three gene sets (two GO pathways
and one set of FDA-approved ADHD genes) in the drug-
gable genome. The Bonferroni-adjusted significance
thresholds for these analyses was set to p= 1.29E−04.
Associations stronger than the determined Bonferroni
thresholds were considered significant.
Step one: analyses of the genes targeted by current ADHD
drugs
We identified 23 genes targeted by the FDA-approved
ADHD drugs (and revealing more than one independent
association signal in ADHD GWA summary statistics).
Individually, none of these genes showed significant asso-
ciation with ADHD (Table 2). For co-morbid conditions,
several significant associations were noted (Table S1). The
strongest one was observed between DRD2 and the fre-
quency of alcohol consumption (p= 2.88E−08), followed
by associations between the same gene (DRD2) and SCZ
(p= 1.55E−07), CYP2D6 and SCZ (p= 1.81E−06),
CHRM2 and major depressive disorder (p= 2.56E−06). In
addition, SLC6A3 revealed significant association with
sleep duration (p= 2.41E−05). All of these genes encode
protein targets of atomoxetine. Furthermore, SLC6A3 is also
targeted by MPH and AMP, while DRD2 is a secondary
target of MPH and AMP.
Examining all the genes as a set revealed no significant
association with neither ADHD nor its co-morbidities
(Table S2).
Step two: analyses of genes and pathways within the
druggable genome
Analyses of genetic variation (MAGMA) For ADHD, four
loci on chromosomes one, three, four and twelve showed
significant association (Table 3). The locus on chromosome
one contains seven druggable genes, while the other three
Table 2 Association between ADHD and genes targeted by FDA-approved ADHD drugs
Target gene FDA approved ADHD drug
Stimulants Non-stimulants







ADRA1A 8 26605667 26724790 469 0.668 N Y N Y N
ADRA1B 5 159343790 159399551 118 0.82 N Y N Y N
ADRA1D 20 4201329 4229721 89 0.499 N N N Y N
ADRA2A 10 112836790 112840658 5 0.43 Y Y Y Y Y
ADRA2B 2 96778707 96781984 5 0.399 Y N N Y Y
CARTPT 5 71014990 71016875 2 0.376 N Y N N N
CHRM1 11 62676151 62689279 25 0.254 N N Y N N
CHRM2 7 136553416 136705002 399 0.049 N N Y N N
CYP2D6 22 42522501 42526908 29 0.689 N N Y N N
DRD2 11 113280318 113346413 167 0.237 N N Y N N
HRH1 3 11178779 11305243 308 0.505 N N Y N N
HTR1B 6 78171948 78173490 5 0.053 N N Y N N
HTR1D 1 23516993 23521222 9 0.301 N N Y N N
HTR2A 13 47405685 47471169 207 0.775 N N Y N N
HTR6 1 19991780 20006055 27 0.026 N N Y N N
HTR7 10 92500578 92617671 305 0.382 N N Y N N
NISCH 3 52489134 52527087 68 0.145 N N N Y N
NPY1R 4 164245113 164265984 48 0.032 N N Y N N
OPRM1 6 154331631 154568001 609 0.217 N Y N N N
SLC18A2 10 119000604 119038941 92 0.347 N Y N N N
SLC6A2 16 55689516 55740104 154 0.223 Y Y Y N Y
SLC6A3 5 1392909 1445545 100 0.836 Y Y Y N Y
SLC6A4 17 28521337 28563020 65 0.483 Y N Y N Y
TAAR1 6 132966123 132967142 3 0.767 N Y N N N
Genes reaching nominal association p-value below 0.05 are highlighted in bold.
“Y” (meaning “yes”) indicates that a gene is targeted by the drug, while “N” (meaning “no”) indicates that a gene is not targeted by the drug. “Chr”
refers to the number of a chromosome where the gene of interest is located. “Start” and “End” refer to base pair location of genes of interest.
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loci contain one druggable gene each (Figs. S1–S4). The
most significant association was observed on chromosome
one (ST3GAL3 gene, p= 3.10E−12, Table 3 and Fig. S1).
While the loci on chromosomes one, four and twelve
revealed strong association signals at the individual SNP
level (Figs. S1–S3), the locus on chromosome three did not
(Fig. S4) and, thus, was excluded from further analyses.
For the co-morbidities, the most significant association
was noted between ITPR3 and rheumatoid arthritis (p=
4.88E−38, Fig. 2 and Table S3). This gene was also
significantly associated with SCZ (p= 1.13E−09). Among
the three loci associated with ADHD, those on chromo-
somes one and four revealed druggable genes also
significantly associated with SCZ, ulcerative colitis, autism
spectrum disorder and the frequency of alcohol consump-
tion (Fig. 2 and Table S3). In addition, educational
attainment showed the highest number of significantly
associated genes (Table S3).
Analyses of gene expression (S-PrediXcan) In total, we
examined 13 tissues of the central nervous system (Fig. S5).
Transcriptome data for 2225 druggable genes (also exam-
ined in MAGMA) were present in at least one tissue of
central nervous system.
For ADHD, the expression levels of two genes—MANBA
(p= 1.63E-07 in”cerebellar hemisphere”) and LEPRE1
(p= 5.05E−09 in “frontal cortex”)—showed significant
association and 18 additional genes showed signs of
suggestive association (p < 0.001) (Table S4).
For co-morbidities, the expression of 13 genes revealed
significant associations with a number of examined
phenotypes (Fig. S5 B-S, Table S4). The most significant
association was observed between the expression of HLA-
DPB1 and rheumatoid arthritis (p= 2.96E-45 in “cerebel-
lum”, Table S4). The expression levels of the two genes that
showed significant association with ADHD (MANBA and
LEPRE1) were also significantly associated with body mass
index, rheumatoid arthritis and SCZ (Table S4).
Overall, gene expression analyses highlighted five
druggable genes significantly associated with ADHD and/
or its comorbidities and quality of life phenotypes in
addition to those prioritised in analyses of genetic variation.
Pathway analyses
For ADHD, no significant association was noted among
either GO or KEGG pathways, with the strongest signal
observed for negative regulation of protein binding
(GO:0032091, p= 1.5E−04). Two GO pathways revealed
nominal associations with ADHD (p < 0.001, Table S5) and
were analysed for association with its co-morbidities and
quality of life phenotypes, showing no significant associa-
tions (Table S5).
The results of KEGG pathways are summarised in
Table S6.
Characterisation of the druggable genome loci
associated with ADHD and/or its co-morbidities and
quality of life phenotypes
Genetic variation loci
Out of the nine druggable genes located within the three loci
significantly associated with ADHD, the proteins encoded
by five of them are interacting with pharmaceuticals that are
FDA-approved or in clinical trials: PTPRF, TIE1, MPL,
SLC6A9 and KCNH3 (Table 3). Among their indications we
noted malignancies, autoimmune diseases, neuropsychiatric
disorders (including ADHD, Parkinson’s and Alzheimer’s
diseases), metabolic disorder, haematopoietic processes,
Table 3 The druggable genes located within the three loci significantly associated with ADHD








Chr1 ST3GAL3 483 3.06E−12 Yes No No No No
KDM4A 71 2.11E−11 Yes No No No No
PTPRF 225 5.06E−10 Yes No No Yes Yes
TIE1 30 2.01E−08 Yes No No Yes Yes
MPL 12 4.69E−08 Yes Yes No Yes Yes
SLC6A9 67 2.39E−07 Yes No No Yes Yes
ARTN 10 3.27E−06 No No No No No
Chr4 MANBA 203 5.99E−08 Yes No No No No
Chr12 KCNH3 40 4.23E−06 Yes No No Yes Yes
“p-value” column indicates the strength of association between a gene and ADHD
ADME: genes involved in the absorption, distribution, metabolism, and excretion of drugs; FDA: United States of America Food and Drug
Administration; SNP: single nucleotide polymorphism
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inflammation, atrial fibrillation and spinal cord injury (Table
S7). No FDA-approved drugs or drugs in clinical trials
interacted with the druggable locus on chromosome four.
For co-morbid conditions, we examined 14 loci within
the druggable genome that all showed suggestive associa-
tion with ADHD (p < 0.001) and significant association
with any of the examined co-morbidities. Among the 17
druggable genes within those 14 loci, 13 interact with drugs
that are in clinical trials or are FDA-approved, with the
majority of indications being autoimmune disorders and/or
malignancies (Table S8).
Gene expression loci
Among the five genes pinpointed by S-PrediXcan (and not
overlapping with those identified in MAGMA), three are
targeted by compounds in clinical trials and two of them are
also FDA-approved. All of these compounds are nutraceu-
ticals, with malignancies and immune dysfunctions among
their indications (Tables S9 and S10).
Discussion
Despite ADHD being a highly heritable disorder, it has
been challenging to utilise genetic information in its treat-
ment. Nonetheless, the more insight we gain into the
molecular genetics of ADHD, the more options for its
treatment may become available [40]. In this study, we
explored the druggable genome in ADHD, its co-morbid
conditions and quality of life phenotypes utilising large-
scale GWA studies. We aimed to address three questions:
(1) do any of the genes encoding targets of FDA-approved
ADHD drugs show association with ADHD and/or its co-
morbidities, (2) are ADHD and/or its co-morbidities and
quality of life phenotypes associated with genetic variation
and expression within the known druggable genome and if
so, (3) can we use those association signals to identify gene
targets for novel drug development and/or repurposing to
treat ADHD.
To answer the first question, we examined the associa-
tion between the genes encoding the immediate targets of
the first-line ADHD pharmacotherapeutics and ADHD as
well as its co-morbidities. We observed no significant
association between these genes and ADHD, suggesting
that these drugs may act through mechanisms different to
those underlying ADHD. However, as the current GWA
study on ADHD reveals only a small fraction of the bio-
logical processes underlying this condition [30], larger
studies are needed to draw any definitive conclusions.
Overall, drugs that are FDA-approved or currently
undergoing clinical trials to treat ADHD (e.g. dasotraline)
target only a limited number of known pharmacological
targets, essentially enhancing catecholamine signalling.
Fig. 2 Tile plot of the association between druggable genes and
ADHD (p < 0.001), its co-morbid conditions of ADHD and quality of
life phenotypes. ADHD; attention deficit/hyperactivity disorder, BMI;
body mass index, CHD; coronary heart disease, T2DM; type 2 dia-
betes mellitus, SWB; subjective well-being
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This illustrates that all active ADHD drugs belong to a
small pharmacological niche and we should aim to move
beyond it. Hence, we examined whether any known drug-
gable genes and pathways are associated with ADHD and/
or its co-morbidities and quality of life phenotypes (second
question), following by pharmacological characterisation of
identified associations (third question). These analyses
aimed to pinpoint novel avenues for ADHD drug devel-
opment as well as repurposing. Because the de novo dis-
covery and development of entirely new drugs targeting
unique biology of a disorder is a tedious and expensive
process with a low success rate, the possibility of repur-
posing already existing drugs towards new indications
may be more effective [40]. Here, we highlight some of
these potential new targets, although this list is not
comprehensive.
Within the loci associated with ADHD, 5 druggable genes
encode proteins interacting with drugs that are FDA-approved
or are in clinical trials. The common indications of those
pharmaceuticals are autoimmune disorders and malignancies,
with some also being tested in clinical trials for treatment of
neurodevelopmental disorders. Interestingly, autoimmune
disorders and malignancies are also common indications for
drugs interacting with genes associated with co-morbidities of
ADHD, suggesting that these two fields of research could
present novel paths for ADHD treatment.
The locus on chromosome one shows the strongest
association with ADHD and also contains the most genes
interacting with drugs that are FDA-approved or in clinical
trials. Among them, PTPRF is the gene with the most
prominent association signal. This gene encodes a tyrosine
phosphatase, a signalling molecule involved in a myriad of
cellular processes, including cell adhesion, neuronal
development and functioning [41, 42]. PTPRF has mainly
been studied in the context of cancer. However, its invol-
vement in hyperactivity [42] and axonal growth [43] has
also been reported. Another ADHD-associated gene inter-
acting with drugs that are FDA-approved and/or are in
clinical trials is SLC6A9, a gene encoding a glycine trans-
porter that is targeted by such compounds as bitopertin,
sarcosine and glycine [44]. In ADHD, glycine supple-
mentation is currently under investigation as a potential
treatment [45]. Similarly, sarcosine has also been tested as a
possible ADHD drug, although the preliminary analyses
indicate that its effect may be limited to oppositional
symptoms only [46].
Outside the chromosome one locus, the KCNH3 gene is
also interacting with drugs that are FDA-approved or are in
clinical trials. This gene encodes a voltage-dependent
potassium channel, a selective inhibitor of which was
recently described [47]. It is also a non-specific target of
blood–brain barrier penetrating drug dalfampridine [48]
used to relieve the symptoms of multiple sclerosis and
related neurologic disorders [44, 49]. Knocking out KCNH3
in mice has been reported to enhance cognitive skills,
including attention, further supporting a potential role of
dalfampridine-like drugs in the treatment of ADHD [50].
The aforementioned druggable genes also showed sig-
nificant association with educational attainment, suggesting
that drugs targeting them may have a possible impact on
quality of life of ADHD patients.
The analyses of correlation between ADHD and gene
expression levels in brain pinpointed druggable genes
MANBA and LEPRE1, among which only LEPRE1 interacts
with a number of compounds in clinical trials, such as
nutraceutical ascorbate, succinic acid and L-proline. This gene
encodes an enzyme needed for collagen synthesis and
assembly, which has recently been proposed as a novel
therapeutic vista for protection and regeneration of neurons
[51]. Moreover, two additional genes, the expression of which
correlated with the examined co-morbidities and quality of
life phenotypes are also targeted by nutraceuticals.
In pathway analyses, the GO pathway of negative reg-
ulation of protein binding (GO:0032091) showed the
strongest, albeit non-significant, association with ADHD.
This pathway encompasses any process that negatively
affects any protein binding, such as actin binding (e.g.
synaptic plasticity), microtubule binding, receptor binding
and homodimerization activity of a protein. The latter pro-
cesses affect a G-protein-coupled receptor signalling, tap-
ping into the largest class of targets in current drug
development [52, 53] and presenting a myriad of potential
opportunities for new drug discoveries in ADHD. Indeed,
one of the novel approaches to pharmacotherapy of ADHD
is the use of fasoracetam that acts on G-protein coupled
glutamate receptor [40].
Among the examined co-morbidities, the neuropsychia-
tric (mostly SCZ) and immune groups revealed significant
associations, with 12 genes interacting with compounds that
are FDA-approved or in clinical trials. Interestingly, one of
these genes is KCNJ13, encoding a druggable potassium
channel targeted by dalfampridine, the same compound that
also targets the KCNH3-protein discussed above.
The gene that revealed significant associations with the
largest number of co-morbidities is SEMA3F. This gene
also showed significant association with educational
attainment. SEMA3F encodes semaphoring-3F protein
involved in cell signalling, affecting cell adhesion and
migration and being explored mostly in cancer therapies
[54, 55]. Nonetheless, the range of therapeutic potential of
semaphorins is large [56].
Our study has some limitations. As we examined asso-
ciations observed in GWA studies, where it is difficult to
obtain adequate sample sizes to detect associations of small
effects, our findings are limited by their statistical power.
Moreover, as we imposed a sample size limit of 20,000
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individuals, some of the co-morbid conditions, where GWA
studies of such size were not available, were replaced by
proxy phenotypes.
The current statistical methods allow us to identify
chromosomal loci only. Further studies on the genes of
interest as well as fine mapping are needed to unambigu-
ously establish which gene(s) lies on the causal pathway to
developing ADHD. This knowledge would allow for a
higher resolution search for therapeutic targets, especially
on chromosome one locus where the LD structure is parti-
cularly complicated.
The gene expression analyses have several limitations
[57], including the confounding by genetic associations due
to LD, implying a possible substantial bias towards genes
located in the loci revealing genome-wide association with
the examined trait. In addition, the available transcriptome
data are limited and are not available in many relevant
tissues (e.g. lack of expression data for KCNH3 in brain
tissues in reference transcriptome), preventing a compre-
hensive investigation of the transcriptome.
As we used publicly available databases, it was not
possible to control their quality. Furthermore, the informa-
tion provided in the utilised drug target databases may be
incomplete.
To conclude, we present a framework for assessment of the
druggable genome in a disorder, exemplified by ADHD. We
present possibilities for drug repurposing (e.g. dalfampridine)
and highlight processes of signal transduction and cell adhe-
sion (negative regulation of protein binding, PTPRF,
SEMA3F, KCNH3, KCNJ13) as potential novel avenues for
ADHD treatment. Our findings add to the knowledge on
known ADHD drugs and present an exploration of druggable
genome associated with ADHD, which may offer intervention
at the aetiological level of the disorder.
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